Effects of LDX on Cognitive Processes and Appetite
Launched by UNIVERSITY OF BIRMINGHAM · Nov 26, 2019
Trial Information
Current as of April 24, 2025
Terminated
Keywords
ClinConnect Summary
This study will investigate the specific reward and cognitive mechanisms that mediate the effects of LDX on eating in participants with sub-clinical binge-eating disorder symptoms. A sub-clinical sample will be recruited in line with the Research Domain Criteria Initiative established by the US National Institute of Mental Health which encourages research on dimensions of observable behaviour rather than a categorical, symptom-based approach to the study of mental health. The tendency towards binge-like eating will be modelled using an eating in the absence of hunger paradigm in which parti...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Fluent English speakers
- • Be willing to be informed of chance pathological findings from the fMRI scan
- • Must have binge-eating symptoms that is measured by a minimum score of 18 on the Binge Eating Scale
- • Must have a minimum BMI of 18.5
- • Must be below 152.4kg
- • Must have clearance from a qualified physician before participating
- Exclusion Criteria:
- • Symptoms or diagnosis of other eating disorders.
- • Psychotherapy and/or pharmacotherapy for binge-eating disorder (BED) 3 months before the study, as this will suggest a diagnosis of BED and may influence eating behaviour.
- • Metabolic (e.g. metabolic disorder, diabetes), psychological (e.g. depression), substance, or neurological (e.g. epilepsy, headache disorder, multiple sclerosis, traumatic brain injuries) diseases or medication in relation to these diseases
- • Intake of any medication that can interfere with the drug or measurements, determined through questionnaires in the screening session
- • Current smoking, as it can interfere with appetite
- • Current pregnancy or breastfeeding
- • Not passing a breathalyser test on the morning of testing.
- • Food allergies (e.g. peanut allergy, lactose and gluten intolerance) or vegetarian/vegan diet
- • Disliking the study lunch to ensure that participants will consume the provided food
- • Women will be asked to participate only in weeks when they are not menstruating or in their pre-menstrual week, to avoid hormonal disruption to appetite.
- The following are exclusion criteria are specific to the MRI scanner:
- • Non-removable metal object in or on their body, such as: heart pace-maker, artificial heart valve, metal prosthesis, implants or splinters, non-removable dental braces
- • Left-handed
- • Tattoos that are older than 10 years
- • Claustrophobia
- • Limited temperature perception and/or increased sensitivity to warming of the body
- • Pathological hearing ability or an increased sensitivity to loud noises
- • Operation less than three months ago
- • Simultaneous participation in other studies that involve drug intake or blood sampling
- • Acute illness or infection during the last 4 weeks
- • Cardiovascular disorders (e.g., hypertrophic cardiomyopathy, long QT syndrome) to ensure medical fitness to participate
- • Moderate or severe head injury
Trial Officials
Suzanne Higgs, PhD
Principal Investigator
University of Birmingham
About University Of Birmingham
The University of Birmingham is a leading research institution in the UK, renowned for its commitment to advancing medical science and improving health outcomes through innovative clinical research. With a strong emphasis on collaboration, the university engages in multidisciplinary studies that leverage cutting-edge technology and expertise across various fields. Its dedicated clinical trial infrastructure supports rigorous investigation and the ethical conduct of research, ensuring that findings contribute meaningfully to the scientific community and public health. Through its initiatives, the University of Birmingham aims to translate research discoveries into tangible benefits for patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials